Scienture, LLC, a wholly owned subsidiary of Scienture Holdings, Inc. (NASDAQ: SCNX) Announces Issuance of a New Patent Covering its first product SCN-102 (Losartan Potassium Oral Suspension, 10mg/mL) through 2041
10 déc. 2024 08h05 HE
|
Scienture Holdings, Inc.
COMMACK, NY and TAMPA, FL, Dec. 10, 2024 (GLOBE NEWSWIRE) -- SCIENTURE, LLC (“the “Company”), a wholly owned subsidiary of SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX), focused on developing and...
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity
26 nov. 2024 08h00 HE
|
35Pharma Inc.
35Pharma Closes Series C Financing to Advance Clinical Pipeline of Activin Inhibitors for Pulmonary Hypertension, Cardiometabolic Disease and Obesity
Phase III trial results of novel triple combination pill for hypertension published in The Lancet
18 oct. 2024 07h00 HE
|
George Medicines
Phase III trial results of novel triple combination pill for hypertension published in The Lancet Novel combination pill significantly reduced blood pressure and improved control rates vs dual...
E-Star BioTech Set to Initiate Phase 2 Clinical Trial of MANP in Resistant Hypertension With Support of Latest Investment
08 oct. 2024 09h00 HE
|
E-Star Biotech
NEW YORK, Oct. 08, 2024 (GLOBE NEWSWIRE) -- E-Star BioTech, LLC (“E-Star” or the “Company”), an innovative developer of novel peptides designed to treat cardiovascular, metabolic, and kidney...
Amwell expands clinical programs portfolio to include Hello Heart cardiovascular health risk management solution
08 oct. 2024 07h05 HE
|
Amwell
Amwell today announced Hello Heart is a partner in the Amwell clinical programs portfolio available on the Amwell Converge™ platform.
Potential of George Medicines’ novel, low-dose, triple combination pill to transform management of hypertension highlighted at global congress
24 sept. 2024 07h00 HE
|
George Medicines
London, UK 24 September 2024 – George Medicines, a late-stage, biopharmaceutical company addressing significant unmet need in the treatment of cardiometabolic disease, today announced the presentation...
Angina Global Market Report 2024: A $13.61 Billion Market in 2028, Registering a Compound Annual Growth Rate (CAGR) of 6.2%
04 sept. 2024 09h26 HE
|
Research and Markets
Dublin, Sept. 04, 2024 (GLOBE NEWSWIRE) -- The "Angina Global Market Report 2024" has been added to ResearchAndMarkets.com's offering.The angina market size has grown strongly in recent years, from...
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024
31 août 2024 03h54 HE
|
George Medicines
George Medicines demonstrates potential of novel, low-dose, triple combination pill to transform management of hypertension in Hot Line Session at ESC Congress 2024 Results from two Phase III trials...
Recor Medical Responds to the American Heart Association’s (AHA) Scientific Statement on Renal Denervation for the Treatment of Hypertension
19 août 2024 09h00 HE
|
Recor Medical
Palo Alto, CA, Aug. 19, 2024 (GLOBE NEWSWIRE) -- Recor Medical, Inc. (“Recor”) and its parent company, Otsuka Medical Devices Co., Ltd. (“Otsuka Medical Devices”) greatly appreciate the American...
George Medicines files New Drug Application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase III development program
06 août 2024 07h00 HE
|
George Medicines
George Medicines files New Drug Application with FDA for novel low dose triple combination for treatment of hypertension following successful international Phase III development program ...